am now long
Deutsche Bank's Top #Biotech Picks For 2015
Kyle Dennis , Benzinga Staff Write
Deutsche Bank " ACHN has alot of upside and a huge Hep C pipeline. We also see buyout in near future".
By Ethan Roberts, InvestorPlace Contributor
Three French healthcare centers have now successfully implanted Second Sight’s Argus II Retinal Prosthesis System into patients with advanced retinitis pigmentosa, an inherited degenerative eye disease that can cause blindness and overall vision impairment. The Argus II is a innovative procedure, with treatmetat approved centers throughout the U.S. and most of Europe. In the past, patients with retinitis pigmentosa had no real treatment and could only postpone their vision loss through Vitamin A supplements
ADXS Was $9 Stock, Only Reason Priced Today By Holding On To ADRO Coat Tails.
do the DD great drugs and what an entry... very nice
Sentiment: Strong Buy
By Paul M. Barrett -March 3, 2015
Second Sight’s ( EYES ) Argus II Retinal Prosthesis System is the first patented and approved retinal prosthesis in the world. Millions stand to benefit from this life-changing technology.
thanks for the update